CureDiab will participate in the 6th Global NASH Congress taking place in London, March 2-3, 2023. On March 3rd, Prof. Juergen Eckel, CEO of CureDiab, will give a presentation entitled “Thioacrylamide-derivatives with hepato-protective and anti-fibrotic activity: A novel first-in-class approach for NASH therapy”. We look forward to inspiring discussions and to contribute to the efforts of developing novel drugs for NASH treatment.
